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Abstract
Background: Researches have shown anti-vascular endothelial growth factor (VEGF) agent is effective in treating
neovascular eye diseases. The purpose of this study is to evaluate the efficacy and safety of intravitreal ranibizumab
(IVR) injection combined trabeculectomy in the treatment of neovascular glaucoma (NVG), and compared it with
Ahmed valve surgery.
Methods: Thirty-six NVG patients (37 eyes) from the First Affiliated Hospital of Zhejiang medical college, between
January 1, 2014 and January 31, 2015, were included in this prospective, interventional clinical study. Eighteen NVG
eyes were given IVR injection one week before trabeculectomy. Ahmed valve implantation surgery was performed
in nineteen eyes. Ocular pain, best corrected visual acuity (BCVA), intraocular pressure (IOP) and surgical
complications were evaluated before and after the surgery.
Results: IOP was significantly decreased following IVR injection combined trabeculectomy treatment (baseline 57.1 ± 8.
9 mmHg; week 1, 15.2 ± 4.3 mmHg p = 0.000; month 1, 16.9 ± 2.1 mmHg p = 0.000; month 3, 20.3 ± 7.7 mmHg p = 0.000;
month 6, 19.7 ± 7.3 mmHg p = 0.000). There was a significant, though modest, BCVA improvement in sighted eyes of IVR
group (baseline 2.42 ± 0.68, W1 1.80 ± 0.91, P = 0.013; M1 1.77 ± 0.93, p = 0.011). IVR injection combined trabeculectomy
had less postoperative complications and lower failure ratio than Ahmed surgery (IVR 5.6 %, Ahmed 31.6 %).
Conclusions: The study revealed that IVR injection combined trabeculectomy was an effective and safe treatment for
NVG. Compared with Ahmed surgery, IVR injection combined trabeculectomy had less complications and higher success
ratio. (Chinese Clinical Registry, TRN ChiCTR-OPN-16008147, 3/24/2016, retrospectively registered)
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Background
Neovascular glaucoma (NVG) is an intractable glaucoma
secondary to the neovascularization of the iris and the
anterior chamber angle. It is caused by ischemia and
hypoxia of the retina in ocular ischemic diseases like
proliferative diabetic retinopathy (PDR), central retinal
vein occlusion (CRVO), etc. NVG is a serious ocular dis-
order with poor prognosis [1, 2]. The management of
NVG is still difficult. Conventional treatments including
filtering surgery, cyclophotocoagulation, cryotherapy, aque-
ous drainage device, panretinal photocoagulation may still
have a high risk of failure to control the intraocular pres-
sure (IOP) and prevent deterioration of the disease [1–3].
Vascular endothelial growth factor (VEGF), a protein
induced by hypoxia and ischemia, is an important regu-
lator in angiogenesis and inflammation responses [4].
VEGF was found highly expressed in neovascular mem-
branes and ocular fluids of neovascular ocular diseases
such as PDR, CRVO and also NVG [5, 6]. Therefore,
VEGF inhibitors were effective in treating neovascular
eye diseases. Ranibizumab (Lucentis), the Fab fragment
of recombinant humanized IgG1kmurine monoclonal
antibody against VEGF-A, was approved for the treat-
ment of ocular neovascular diseases such as wet age-
related macular degeneration [7, 8]. The utilization of
ranivizumab has been expanded to treat many diseases
with macular edema such as PDR, CRVO and NVG in
recent years [9, 10]. There are several studies about bev-
acizumab, another anti-VEGF agent off-label used in
ocular neovascular diseases, which has served as an ef-
fective medicine in treating NVG [11–13]. But clinical
trials about the efficacy and safety of the ranibizumab in
treating NVG are relatively rare.
Our study was designed to test the efficacy of intravit-
real ranibizumab (IVR) injection combined with trabecu-
lectomy with mitomycin C (MMC) on patients with
NVG. We also compared its efficacy and safety with the
conventional treatment, Ahmed valve surgery, to evalu-
ate advantages and disadvantages of these two therapies
separately.
Methods
Patients and inclusion criteria
The study was a prospective interventional study includ-
ing 36 patients with 37 NVG eyes. Randomized placebo-
controlled design was not conducted because the poor
prognosis of NVG left no room for ethical randomization.
NVG patients were treated in the ophthalmology depart-
ment of the First Affiliated Hospital of Zhejiang medical
college, Zhejiang University, Hangzhou, China, between
January 1, 2014 and January 31, 2015. The study was ap-
proved by the Ethics Committee of the First Affiliated
Hospital of Zhejiang University and it was performed in
accordance with the tenets of the Declaration of Helsinki.
All patients were aware of their therapy. An informed
consent form was signed by every patient.
Patients were included in the study based on the fol-
lowing criteria: (i) age > 20 years; (ii) diagnosed as NVG
with rubeosis; (iii) IOP > 21 mmHg with the maximum
use of anti-glaucoma drugs. Exclusion criteria included:
(i) active ocular infection; (ii) previous glaucoma filtering
surgery; (iii) previous anti-VEGF treatment; (iv) any
contraindication of intraocular injection or surgery, such
as high risk of bleeding, pregnancy, and infection, et al.
NVG patients received one of two types of treatment:
IVR injection and subsequent trabeculectomy with
MMC, or Ahmed valve implantation surgery. Main med-
ical history and previous treatments were recorded.
IVR injection and surgical techniques
All surgeries and intravitreal injections were performed
by Dr. Xiaoyu Wang and Dr. Lan Liu. Eighteen eyes with
NVG received IVR injection under topical anesthesia in
the aseptic condition of an operating room. 0.5 mg
(0.05 ml) Ranibizumab was injected through the pars
plana with a 25G needle. The patients were given topical
antibiotics and previous antiglaucoma medicines for
1 week after injection. The surgery of trabeculectomy
with MMC was performed 1 week later. The globe was
pulled inferiorly by a traction suture. The conjunctival
incision was made along the limbus to create a fornix-
based conjunctival flap in the superotemporal quadrant.
A half thick 4 mm × 4 mm square scleral flap was made.
MMC (0.4 mg/ml) soaked sponge was placed under the
scleral flap for 1 to 2 min. Then the area was irrigated
with plenty of saline. Trabecular meshwork (1 × 1.5 mm)
was cut and the peripheral iridectomy (1 × 1 mm) was
preformed. The scleral flap was closed with two 10-0
nylon sutures at its corners. The conjunctiva was su-
tured with 8-0 vicryl sutures.
Ahmed valve implantation surgery was performed on
nineteen NVG eyes and the procedure was described as
follows. A fornix-based conjunctival and Tenon’s flap
was created in the superotemperal quadrant. The
Ahmed valve implantation (Model FP7, New World
Medical, Inc.) was inserted into the Tenon’s capsule and
fixed on the sclera 8 mm posterior to the limbus with 8-
0 sutures. A 4 mm × 4 mm square scleral flap was made,
a corneoscleral track was made by a 23-gauge needle
and the tube was inserted into the anterior chamber
through the scleral flap. The tube was fixed to the epi-
sclera with 8-0 sutures. Topical eyedrops of antibiotics
and steroids were used in every patient for two weeks.
Outcome measurement and follow-up
Pain of the patients was assessed and recorded by nu-
merical rating scale (NRS), ranging from 0 (no pain) to
10 (worst imaginable pain). Best corrected visual acuity
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(BCVA), IOP (Goldmann applanation tonometer), angle
status and full ophthalmic examination were taken before
and after the surgery. BCVA was recorded using logMAR
equivalent, and counting fingers was assigned value 2,
hand movement was assigned 3. The new vessels of iris
were observed by slip lamp. Surgical complications and
postoperative anti-glaucoma medications were also re-
corded. The patients were followed up for at least 6 month
and the IOP and BCVA were recorded on day 1, week 1,
then monthly after the operation. The staff members per-
forming the NRS, BCVA and IOP assessment were not in-
volved in implementing the surgeries.
The efficacy of the treatment was evaluated by the suc-
cess of the surgery. Complete success was defined as
IOP ≥ 6 mmHg and ≤ 21 mmHg without any anti-
glaucoma medications or further glaucoma surgery, and
without loss of light perception. Partial success was de-
fined as IOP < 21 mmHg with topical anti-glaucoma
medicines. Surgical failure was defined as IOP ≥
21 mmHg even with anti-glaucoma medicines, or add-
itional surgical treatment was needed to control IOP, or
loss of light perception.
Statistical analysis
Statistical analysis was conducted using the software
SPSS 10.0 (SPSS, Inc. Chicago, IL). Independent and
paired Student t-test was used to assess differences be-
tween groups. Results were presented as mean ± stand-




Thirty-six NVG patients (37 eyes) were included in the
study. Eighteen NVG eyes underwent IVR injection and
subsequent trabeculectomy (IVR group). Nineteen eyes
underwent Ahmed valve implantation surgery (Ahmed
group). The patients’ demographics and basic character-
istics were summarized in Table 1. There were no differ-
ences in the gender and age between the two groups. Of
all 37 NVG eyes, 14 (37.8 %) were caused by PDR, 18
(48.6 %) by CRVO, 1 (2.7 %) by branch retinal vein oc-
clusion (BRVO), 1 (2.7 %) by ischemic optic neuropathy,
and 3 (8.1 %) were after the intraocular surgery. There
were no differences among the causes between two
groups. The baseline IOP was 57.1 ± 8.9 mmHg in the
IVR group and 49.8 ± 11.8 mmHg in the Ahmed group.
Baseline BCVA of sighted eyes was 2.42 ± 0.68 in the
IVR group and 2.51 ± 0.84 in the Ahmed group. No dif-
ferences were found in baseline IOP (p = 0.12) and
BCVA (p = 0.68) between the two groups. Sixteen eyes
(88.9 %) in the IVR group and 17 eyes (89.5 %) in the
Ahmed group were given retinal photocoagulation be-
fore the operation, and no differences were found
between the two groups. Two eyes in the IVR group and 3
eyes in the Ahmed group were given additional retinal
photocoagulation after the operation to prevent deterior-
ation due to the diseases. There were 3 patients (1 in the
IVR group, 2 in the Ahmed group) who experienced enu-
cleation in month 3 due to the uncontrolled high IOP and
unbearable eye pain, and were lost to follow-up.
Rubeosis regression and pain relief
Rubeosis was found in all 37 NVG eyes (100 %) and
hyphema in 3 patients (8.1 %) before treatment. In the
IVR group, the new vessels of the iris apparently
regressed in all 18 eyes after the IVR injection (Fig. 1).
The eye pain (NRS score) was significantly relieved one
week after trabeculectomy (before surgery 6.4 ± 0.8; one
week 2.2 ± 0.5 p = 0.000), and had almost disappeared
one month later(0.3 ± 0.5, p = 0.000). In the Ahmed
group, the pain was also significantly decreased at one
week (5.7 ± 1.0; one week, 2.6 ± 0.96, p = 0.000) and al-
most vanished one month later (0.5 ± 0.7, p = 0.000,
Table 2). The NRS score remained low in both groups at
Table 1 Baseline characteristics of included patients
IVR and trabeculectomy
with MMC (n = 18)
Ahmed valve
surgery (n = 19)
P value



















































Pain grade (NRS) 6.44 ± 0.78 5.68 ± 1.00 0.33
Abbreviations: NVG neovascular glaucoma, PDR proliferative diabetic
retinopathy, CRVO central retinal vein occlusion, BRVO branch retinal vein
occlusion, IOP intraocular pressure, BCVA best corrected visual acuity, NLP no
light perception, LP light perception, IVR intravitreal ranibizumab, MMC
mitomycin C
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month 3 and month 6, except 1 patient in IVR group, 2
in Ahmed group had increased NRS score (IVR 7,
Ahmed 8) owing to the uncontrolled IOP.
IOP
In the IVR group, IOP was significantly decreased (week
1, 15.2 ± 4.3 mmHg p = 0.000; month 1, 16.9 ± 2.1 mmHg
p = 0.000; month 3, 20.3 ± 7.7 mmHg p = 0.000; month 6,
19.7 ± 7.3 mmHg p = 0.000) after trabeculectomy com-
pared with the baseline IOP (57.1 ± 8.9 mmHg). But IOP
was only slightly lowered after IVR injection (55.9 ±
6.9 mmHg, p = 0.154). There was also a significant drop
of IOP in the NVG eyes of the Ahmed group (W1 12.8 ±
8.7 mmHg p = 0.000, M1 19.7 ± 4.5 mmHg p = 0.000, M3
24.9 ± 14.2 mmHg p = 0.000, M6 22.8 ± 11.2 mmHg
p = 0.000) (Fig. 2.). Results showed that IOP was signifi-
cantly lower in the IVR group than that in the Ahmed
group at month 1 (P = 0.021). There were no differences
of IOP between the two groups at week 1 (P = 0.302),
month 3 (P = 0.225) and month 6 (P = 0.324).
BCVA
Visual acuity was relatively low in all NVG patients.
Mean BCVA of sighted eyes (n = 26) was 2.46 ± 0.75
(IVR 2.42 ± 0.68, Ahmed 2.51 ± 0.84), and 5 eyes showed
light perception (LP), 6 had no light perception (NLP)
(Table 1). Results showed that there was a significant
BCVA improvement at week 1 and month 1 in the IVR
group (W1 1.80 ± 0.91, P = 0.013; M1 1.77 ± 0.93, p =
0.011) compared with the baseline, though the improve-
ment was relatively modest. BCVA was not significantly
increased in the Ahmed group (W1 1.92 ± 1.24, P =
0.156; M1, 2.53 ± 0.85, p = 0.252, Table 2). Visual acuity
of all NVG patients in both groups maintained stable
after month 1, except 1 patient in the IVR group and 2
in the Ahmed group who lost light perception due to
the uncontrolled IOP at month 3.
Complications
There were no intraoperative complications in either the
IVR or the Ahmed group. There were apparently more
postoperative complications in the Ahmed group than in
the IVR groups (Table 3), especially in the early postop-
erative period (within two weeks of the surgery). Six eyes
were found with low IOP (hypotony, IOP ≤ 5 mmHg), 2
eyes with shallow anterior chamber, 1 eye with no anter-
ior chamber which needed additional surgery, and 1 eye
with hyphema and 1 eye with exudative inflammation at
week 1 in the Ahmed group. There were no early com-
plications in the IVR group. In the late postoperative
period (after two weeks), 3 eyes (16.7 %) with complica-
tions (hyphema, vitreous hemorrhage and high IOP) were
found in the IVR group. There were obviously more com-
plications in the Ahmed group (8 eyes, 42.1 %).
In the IVR group, 11 eyes (61.1 %) were maintained
IOP < 21 mmHg without anti-glaucoma medications
(complete success), 6 eyes (33.3 %) maintained IOP <
21 mmHg with medications (partial success), 1 eye
(5.6 %) failed to control IOP even with anti-glaucoma
medications. In the Ahmed group 11 eyes (57.9 %) had
complete success, 2 eyes (10.5 %) partial success and 6
eyes (31.6 %) failed.
Fig. 1 Anterior segment photography of a neovascular glaucoma patient before and after intravitreal ranibizumab injection (IVR). a. Massive new
vessels (black arrows) were seen on the iris around the pupil before IVR. b. New vessels were regressed (black arrows) three days after IVR from
the same patient of A
Table 2 NRS scores and BCVA of neovascular glaucoma
patients
IVR group (n = 18) Ahmed group (n = 19)
NRS scores
Before surgery
1 week after surgery









1 week after surgery







Abbreviations: IVR intravitreal ranibizumab, NRS numerical rating scale, BCVA
best corrected visual acuity
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Discussion
NVG is a serious and refractory glaucoma with poor
prognosis. There are no optimal treatments that would
cure the disease. Conventional treatment would still fail
due to the recurrence of neovascularization [14]. In our
study, we evaluated the efficacy of IVR injection com-
bined with trabeculectomy in treating NVG patients,
and which we also compared with treatment of Ahmed
valve surgery. Our results showed that IVR injection
evidently reduced the new vessels of the iris, IVR com-
bined trabeculectomy effectively relieved the ocular pain,
controlled IOP, and partially improved BCVA. Compared
with the Ahmed valve surgery, the IVR combined trabe-
culectomy treatment had less postoperative complica-
tions and lower failure ratios.
NVG is caused by the neovascularization and fibration
of the anterior chamber angle and iris, and results in un-
controlled IOP and ocular pain. Proper management
should include the treatment of the underlying disease
and the high IOP [2, 15]. Trabeculectomy was consid-
ered the most effective surgical procedure for reducing
IOP in patients with primary open-angle glaucoma and
primary angle-close glaucoma [16, 17]. But the manage-
ment of NVG is still highly challenging and controver-
sial. Trabeculectomy alone had a high risk of failure to
control IOP of NVG, due to the bleb adhesion by neo-
vascularization in the anterior chamber angle [2]. Im-
proper treatment would finally result in blindness and
intractable ocular pain. In managing NVG, it is import-
ant to treat underlying causes in addition to the elevated
IOP [15]. VEGF is the key angiogenic factor in the
pathogenesis of neovascular ocular diseases such as
NVG [18]. Inhibition of VEGF also markedly reduced
the fibroblast proliferation and scar formation after glau-
coma filtration surgery [19, 20]. Therefore, anti-VEGF
antibody served as a useful adjunctive to the therapy of
NVG via its anti-angiogenic and anti-fibrotic properties
[21]. In our study, we treated 18 NVG eyes with anti-
VEGF drugs (ranibizumab) before the trabeculectomy
Fig. 2 Mean intraocular pressure (IOP) before and after the surgery in intravitreal ranibizumab injection (IVR) group and Ahmed surgery (Ahmed)
group. *, P < 0.05 compared with the baseline of IVR group, #, P < 0.05 compared with the baseline of Ahmed group. NS, P > 0.05 compared with
the baseline of IVR group
Table 3 Intraoperative and postoperative complications





















Shallow or no anterior chamber
High IOP













subtotal 3(16.7 %) 8(42.1 %)
total 3 19
aEarly postoperative: within two weeks after the surgery; bLate postoperative:
after two weeks of the surgery
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with MMC. We found that IVR injection could signifi-
cantly decrease the iris neovascularization and partly
lower IOP. Since neovascularization was the main cause
of NVG, IVR injection might provide chances to in-
crease the success probability of the subsequent anti-
glaucoma surgery.
Recent studies have shown outstanding efficacy of
anti-VEGF agents (bevacizumab, ranibizumab) in treat-
ing neovascular eye diseases, such as age-related macular
degeneration [7, 8]. Several studies have shown that
bevacizumab injection was a useful adjuvant for the
treatment of NVG [11, 12]. Intraocular injection of bev-
acizumab could significantly reduce the new vessels in
the anterior chamber angle, lower IOP and decrease the
aqueous VEGF concentration [22, 23]. The study by
Klettner and Roider revealed ranibizumab was more effi-
cient than bevacizumab in neutralizing VEGF in vitro
[24]. And due to the off-label use of bevacizumab in eye
diseases, ranibizumab (Lucentis) should be more suitable
in treating NVG. There were no randomized controlled
trials (RCTs) using anti-VEGF agents for the treatment
of NVG [25], while there are a few studies about uses of
ranibizumab in NVG. Artilces by Elmekawey and Kitnarong
[26, 27] showed that intracameral or intravitreous injection
of ranibizumab combined trabeculectomy effectively con-
trolled IOP of NVG. A study by Li et al. [28] found that
IVR combined vitrectomy, lensectomy, retinal photocoagu-
latin and trabeculectomy could control IOP and improve
BCVA for NVG patients with vitreous hemorrhage. Luke et
al [29] used IVR alone and showed, with repeated injec-
tions, it was beneficial for treating NVG. Desai et al [30]
found that intravitreal injection of ranibizumab was an
effective adjunctive treatment to Ahmed tube surgery in
open-angle glaucoma. In our study, we conducted intravit-
real injection of ranibizumab before trabeculectomy, and
compared its efficacy and complications with the conven-
tional Ahmed valve surgery. Our results revealed that the
treatment of IVR injection combined trabeculectomy in-
duced apparent regression of iris new vessels, significantly
relieved eye pain, lowered IOP and partially improved
BCVA in NVG patients. The high ratio of complete and
partial success supported the efficacy of IVR injection com-
bined trabeculectomy in treatment of NVG.
A Glaucoma drainage device (such as Ahmed valve
implantation) was usually chosen as a common option
to treat the secondary glaucoma in complex cases like
NVG [2]. We compared the efficacy and complications
of IVR + trabeculectomy treatment with the treatment of
Ahmed valve surgery on NVG in our study. Our results
showed that while Ahmed valve surgery also significantly
relieved the eye pain, lowered IOP and partially im-
proved BCVA, compared with IVR injection with trabe-
culectomy, Ahmed valve surgery markedly increased the
postoperative complications, especially in the early
postoperative stage, such as shallow or no anterior
chamber, hyphema and hypotony. These complications
ultimately increased the failure probabilities of the
Ahmed surgery. Results showed that there was lower
failure ratio in the IVR group compared with the Ahmed
group.
Overall our study showed that IVR combined trabecu-
lectomy would be an effective and safe treatment for
NVG. Further clinical trials with larger sample numbers
are needed to provide more evidence to define this opti-
mal treatment of NVG.
Conclusions
Our study demonstrated IVR injection combined trabecu-
lectomy was an effective and safe treatment for NVG.
Compared with Ahmed surgery, IVR injection combined
trabeculectomy had less complications and higher success
ratio.
Abbreviations
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